Biotech Values

[DewDiligence]

AUXL/QLTI—When completed, Auxilium shareholders will own approximately 76% of the combined entity on a fully diluted basis, and current QLT shareholders will own approximately 24%, subject to certain adjustments.

They barely cleared the 20% threshold needed for a tax inversion (#msg-101714163).

Due to the re-incorporation in Canada, the deal is fully taxable to AUXL shareholders.

QLTI is the company that once made good money selling Visudyne, a rather barbaric photodynamic therapy for wet AMD. Visudyne sales quickly collapsed when Lucentis was launched in 2006.